

# Anthony J Garcia-Prats

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6836001/publications.pdf>

Version: 2024-02-01

70  
papers

1,340  
citations

393982

19  
h-index

414034

32  
g-index

71  
all docs

71  
docs citations

71  
times ranked

1364  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	3.9	96
2	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	5.2	80
3	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	3.1	71
4	Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2015, 60, 549-556.	2.9	62
5	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1300-1310.	2.5	61
6	Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations. <i>Tuberculosis</i> , 2014, 94, 93-104.	0.8	51
7	A review of the use of ethionamide and prothionamide in childhood tuberculosis. <i>Tuberculosis</i> , 2016, 97, 126-136.	0.8	51
8	Fluoroquinolones for the treatment of tuberculosis in children. <i>Tuberculosis</i> , 2015, 95, 229-245.	0.8	48
9	Pharmacokinetics of Ofloxacin and Levofloxacin for Prevention and Treatment of Multidrug-Resistant Tuberculosis in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2948-2951.	1.4	47
10	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. <i>PLoS Medicine</i> , 2019, 16, e1002789.	3.9	41
11	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	37
12	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). <i>Trials</i> , 2018, 19, 693.	0.7	36
13	Adverse effects of oral second-line antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1369-1381.	1.0	29
14	Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. <i>PLoS Medicine</i> , 2019, 16, e1002882.	3.9	27
15	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3237-3246.	1.3	26
16	Managing multidrug-resistant tuberculosis in children. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 211-219.	1.3	25
17	Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, 1777-1780.	2.9	24
18	Listening panel agreement and characteristics of lung sounds digitally recorded from children aged 1â€“59 months enrolled in the Pneumonia Etiology Research for Child Health (PERCH) caseâ€“control study. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000193.	1.2	23

#	ARTICLE	IF	CITATIONS
19	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2384-2392.	1.1	23
20	Antituberculosis drugs in children. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 252-265.	2.3	21
21	Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 706-708.	1.1	20
22	Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 662-664.	5.2	19
23	Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1292-1298.	0.6	18
24	Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 233-244.	1.3	18
25	Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 636-645.	2.7	18
26	Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. <i>Clinical Infectious Diseases</i> , 2020, 70, 425-435.	2.9	18
27	False-negative post-18-month confirmatory HIV tests in HIV DNA PCR-positive children. <i>Aids</i> , 2012, 26, 1927-1934.	1.0	17
28	Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children. <i>Journal of the International AIDS Society</i> , 2015, 18, 20236.	1.2	17
29	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6073-6079.	1.4	17
30	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	16
31	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2019, 25, 441-450.	2.0	16
32	Completeness and accuracy of electronic recording of paediatric drug-resistant tuberculosis in Cape Town, South Africa. <i>Public Health Action</i> , 2013, 3, 214-219.	0.4	14
33	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	14
34	Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa. <i>EclinicalMedicine</i> , 2020, 20, 100290.	3.2	14
35	The safety and tolerability of the second-line injectable antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1491-1500.	1.0	13
36	Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. <i>Clinical Infectious Diseases</i> , 2022, 74, 1372-1381.	2.9	13

#	ARTICLE	IF	CITATIONS
37	Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities. <i>Pathogens</i> , 2022, 11, 381.	1.2	13
38	Acquired Drug Resistance During Inadequate Therapy in A Young Child with Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 883-885.	1.1	12
39	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 589-598.	0.9	12
40	Tuberculosis in children with severe acute malnutrition. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 273-284.	1.0	12
41	Tuberculous Pericardial Effusions in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 346-349.	0.6	10
42	Treatment of Multidrug-resistant Tuberculosis Infection in Children. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 831-834.	1.1	10
43	Drug-resistant tuberculosis: will grand promises fail children and adolescents?. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 237-238.	2.7	9
44	Treatment of Multidrug-Resistant Tuberculosis Infection in Children. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1061-1064.	1.1	9
45	HIV-associated pediatric tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 501-506.	1.5	8
46	Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 608-610.	1.1	8
47	Mitigating the Impacts of COVID-19 on Global Child Health: a Call to Action. <i>Current Tropical Medicine Reports</i> , 2021, 8, 183-189.	1.6	8
48	Opportunities for Mobile App-Based Adherence Support for Children With Tuberculosis in South Africa. <i>JMIR MHealth and UHealth</i> , 2020, 8, e19154.	1.8	8
49	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2022, 75, 1772-1780.	2.9	8
50	Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0214421.	1.4	8
51	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1199-1203.	1.1	7
52	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
53	High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2022, Publish Ahead of Print, .	1.1	7
54	Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis: Figure 1.. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e41-e44.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 604-608.	1.1	6
56	Toxicity and Tolerability of Fluoroquinolone-based Preventive Therapy for Childhood Contacts of Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1098-1099.	1.1	5
57	Multidrug-Resistant Tuberculosis in Children: Recent Developments in Diagnosis, Treatment and Prevention. <i>Current Pediatrics Reports</i> , 2016, 4, 53-62.	1.7	4
58	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1067-1073.	2.9	4
59	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 722204.	1.6	3
60	Drug concentration at the site of disease in children with pulmonary tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1710-1719.	1.3	3
61	The time has come: sparing injectables in paediatric MDR-TB. <i>Lancet Respiratory Medicine</i> , 2017, 5, 245-246.	5.2	2
62	Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 436-445.	2.9	2
63	Caregiver-child separation during tuberculosis hospitalisation: a qualitative study in South Africa. <i>South African Journal of Psychology</i> , 2021, 51, 409-421.	1.0	2
64	Pediatric COVID-19 Therapeutics. <i>Pediatric Infectious Disease Journal</i> , 2021, Publish Ahead of Print, e1-e5.	1.1	2
65	In Reply. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1205-1206.	1.1	1
66	Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt. <i>Clinical Infectious Diseases</i> , 2017, 65, 704-705.	2.9	1
67	The determination of capreomycin in human plasma by LC-MS/MS using ion-pairing chromatography and solid-phase extraction. <i>Biomedical Chromatography</i> , 2018, 32, e4269.	0.8	1
68	Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 161-174.	1.3	1
69	The association between enteropathogens and antimycobacterial drug pharmacokinetics in children. <i>Lancet Microbe</i> , The, 2022, , .	3.4	0
70	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0226421.	1.4	0